Legochem Biosciences to join Bio Europe and Jefferies Conference

LegoChem Biosciences Joins BIO Europe 2026 and Jeffries Conference

A global biotechnology firm is accelerating its partnering discussions by taking its pipeline to two major international industry events, according to Newsis.

LegoChem Biosciences announced on the 9th that it will participate in BIO Europe 2026 in Cologne, Germany, from the 9th to 11th. Following that European partnering gathering, the company will travel to London for the Jeffries Global Healthcare Conference from the 16th to 19th.

Global Partnering in Cologne

BIO Europe brings together more than 2,000 pharmaceutical and biotechnology companies and global investment institutions from roughly 60 countries every year, Newsis reported. LegoChem Biosciences plans to hold one-on-one meetings with multiple global drugmakers during the event.

Discussions will center on out-licensing its clinical and preclinical proprietary pipelines and licensing its next-generation antibody-drug conjugate (ADC) platform. The company will showcase pipelines built on its ConjuAll platform, including the HER2 ADC IKS014 and CD19 ADC IKS03, which are being developed by its partner Iksuda Therapeutics, alongside new pipelines based on its next-generation DAR1 platform.

Two-Track Strategy in London

At the Jeffries Global Healthcare Conference, LegoChem Biosciences will present its two-track strategy to global institutional investors and business development officials from pharmaceutical companies, according to Newsis.

We will use these events to accelerate technology transfer discussions while further expanding our partnership opportunities, said Chae Je-wook, Senior Vice President at LegoChem Biosciences, as reported by Newsis.

Investor and Industry Questions

What platforms are featured in the licensing talks?

LegoChem Biosciences is highlighting its ConjuAll platform and next-generation DAR1 platform during its partnering discussions. These technologies underpin clinical and preclinical assets such as the HER2 ADC IKS014 and CD19 ADC IKS03.

Who is the industry partner developing specific assets?

Iksuda Therapeutics is developing the HER2 ADC IKS014 and CD19 ADC IKS03 utilizing LegoChem Biosciences platforms, according to Newsis.